Clever Culture Systems (CC5) H2 2025 earnings summary

Executive summary

• Achieved a financial turnaround with net profit after tax of $1.68 million for FY25, reversing a $3.74 million loss in FY24.

• Revenue reached $6.63 million, driven by 11 APAS® Independence instrument sales to top-tier pharmaceutical customers.

• APAS® Independence established as a leading technology in pharmaceutical environmental monitoring, with installations at AstraZeneca, Novo Nordisk, Bristol Myers Squibb, Patheon Pharma Services, and Pfizer.

• Launched a new contact plate analysis module, expanding addressable market and recurring revenue opportunities.

• Strong sales pipeline with over 40 qualified leads and more than 150 potential future instrument sales.

Financial highlights

• Net profit after tax: $1.68 million (FY24: $3.74 million loss).

• Revenue: $6.63 million (FY24: $1.71 million).

• Cash and receivables: $5.1 million at year-end.

• Gross margin: $5.28 million revenue from APAS® sales, license fees, and support; $1.5 million cost of goods sold.

• Income tax benefit: $1.77 million, supporting profitability.

Outlook and guidance

• Focus on executing the "Land and Expand" strategy to secure new top-tier pharmaceutical customers and expand within existing networks.

• Anticipates further customer wins, new data releases, and acceleration of sales in FY26.

• Early customer adoption and validation expected to drive broader market acceptance and recurring revenues.